Loading clinical trials...

COMPLETEDPHASE3

A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults

NCT00250432•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast infections)

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Clinical and Laboratory evidence of blood stream \&/or systemic candida infections

Exclusion Criteria

•Possible candida contamination
•Candida colonization (non invasive infection), urine, cardiac, bone or brain and prosthetic device infections
•Acute or moderately severe liver disease
•Abnormal liver function tests
•Abnormal blood clotting for patients on blood thinners

Key Dates

Start Date

January 1, 2006

Primary Completion Date

January 1, 2008

Completion Date

March 1, 2008

Last Updated

March 24, 2017

Enrollment

204

ACTUAL participants

Conditions

Invasive Candidiasis

Interventions

caspofungin acetate

DRUG

Early Discontinuation of Empirical Antifungal Therapy and Biomarkers

NCT03538912

Invasive Candidiasis

View study

COMPLETED

NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis

NCT02801682

Invasive Candidiasis

View study

COMPLETEDPHASE1

Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation

NCT01666769

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 24, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

Inclusion Criteria

Exclusion Criteria

Early Discontinuation of Empirical Antifungal Therapy and Biomarkers

NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis

Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation

Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)

CRITIC - Treatment of Candidemia and Invasive Candidiasis